Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of body weight on trough concentrations of direct oral anticoagulants
NL-OMON22392Unknown
- Sponsor
- HagaZiekenhuis
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of dabigatran, edoxaban, apixaban and rivaroxaban in thromboembolism (4 cohorts), sponsored by HagaZiekenhuis. Primary endpoint: DOAC trough concentration. Status: unknown.
02
Drugs
dabigatranedoxabanapixabanrivaroxaban
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NL-OMON22392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22392.